MYX.AX
MYX.AX
AU000000MYX0
M PHARMA FPO [MYX]
Loading chart...

Company Profile

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Related stocks

7476.T
7476.T • Japan
AS ONE CORPORATION
2,495 JPY
1.12B USD 1Y -1.2%
603368.SS
603368.SS • China
GUANGXI LIUYAO GROUP CO LTD
15.48 CNY
920.07M USD 1Y -18%
EBO.NZ
EBO.NZ • Australia
Ebos Group Limited Ordinary Sha
18.98 NZD
2.23B USD 1Y -36.1%
200028.SZ
200028.SZ • China
ACCORD-B
12 HKD
936.21M USD 1Y -3.3%
600739.SS
600739.SS • China
LIAONING CHENGDA
10.33 CNY
2.35B USD 1Y -17%
9987.T
9987.T • Japan
SUZUKEN CO LTD
2,600 JPY
2.19B USD 1Y -12.6%
000950.SZ
000950.SZ • China
CQP
5.34 CNY
1.37B USD 1Y +3.5%
008930.KS
008930.KS • South Korea
Hanmi Science
54,900 KRW
2.78B USD 1Y +44.1%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
61.2% p.a.
Max Drawdown (5Y)
-72.3%
Sharpe Ratio (5Y)
-0.28
Beta Factor
1.02
Size Class
Micro Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (61.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -94.5% in the extended horizon.
ende